logo
ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENS ai™ Platform Powered by Patented HYFT ® Technology

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENS ai™ Platform Powered by Patented HYFT ® Technology

Business Wire24-06-2025
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise (NASDAQ: IPA), a leader in AI-driven biotherapeutics, provides a significant update following its June 5, 2025, press release ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery. This new release details the downstream validation of the epitope identified in that initial announcement—demonstrating that the computationally selected vaccine target is not only highly conserved across all four dengue virus types but also safe, immunologically active, and structurally stable.
ImmunoPrecise's patented HYFT technology successfully identified a critical and discontiguous target site (epitope) that remains unchanged across all four types of dengue virus (DENV-1 through DENV-4).
'This is a major step forward,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'Our AI technology not only found a new target for a universal dengue vaccine, but we've now shown it's safe and can trigger the right immune response. With this validation, we're excited to move ahead and advance this candidate toward the next stages of vaccine development.'
Following the recent discovery of a unique 'Achilles' heel' shared by all four types of dengue virus, ImmunoPrecise has confirmed—using its patented HYFT technology and LENS ai Immunogenicity Screener—that the selected target not only remains conserved but also triggers a strong and specific immune response. This breakthrough may pave the way for a safer, more universal dengue vaccine.
The new target was discovered using the Company's proprietary LENS ai platform. 'Our ability to move from computational discovery to AI-guided immunogenicity validation is unique to our methodology and drug development,' commented Dr. Jennifer Bath, ImmunoPrecise CEO. 'Further, it ensures that our candidates are both theoretically promising and primed for real-world immune protection, a critical requirement for any viable vaccine candidate.'
For decades, dengue has been one of the most challenging viruses for vaccine developers, largely because the virus comes in four different forms—and beating one doesn't guarantee protection from the others. Many vaccines fail because they trigger the immune system to attack the wrong parts of the virus, or worse, make infections more severe. What makes this development so important is that ImmunoPrecise's target has now been shown—based on in silico immune profiling—to likely engage key components of the immune system, including both B cells and T cells, in a manner that appears safe and highly specific. ImmunoPrecise's latest AI-driven testing shows that their selected target—a small, stable piece of the virus—can activate the body's defenses in a very precise way, without the risks of traditional, broader approaches.
A Methodology That Changes the Game—Far Beyond Dengue
What sets ImmunoPrecise apart is not only the discovery of a promising dengue vaccine target, but the methodology itself. With LENS ai powered by HYFT technology, IPA brings unprecedented clarity to the earliest stages of discovery—well before traditional disease modeling or animal studies even begin. By revealing deep relationships between sequence, structure, and function at the outset, this platform provides rapid, explainable insights that inform every downstream decision, from epitope selection to vaccine design.
The findings for dengue showcase the platform's versatility. Because HYFT technology systematically maps biological meaning across the entire biosphere, this methodology is readily transferable—equipping IPA to tackle a wide spectrum of infectious diseases, from HIV and influenza to emerging pathogens and oncology targets. With this approach, ImmunoPrecise isn't just keeping pace with the field; it's setting a new standard for how next-generation therapeutics are discovered and validated.
ImmunoPrecise's patented HYFT technology successfully identified a critical and discontiguous target site (epitope) that remains unchanged across all four types of dengue virus (DENV-1 through DENV-4). This target site is essential for how the virus infects cells and is believed to be key for establishing an enduring and efficacious universal dengue vaccine.
This HYFT-guided workflow achieves this by analyzing protein building blocks that may be far apart in the virus's genetic sequence but come together when the protein folds into its final 3D shape. This advanced mapping process combines genetic similarity analysis with 3D structural modeling and functional annotation to identify the most promising vaccine targets.
Key Technical Findings
Complete Immune Response Testing
Computer-based immune response screening used advanced prediction tools to evaluate how both antibody-producing cells (B cells) and infection-fighting cells (T cells) would respond to the vaccine target. The target site showed strong predicted binding to multiple human immune system markers (HLA class I and II types). This suggests that people from diverse backgrounds and genetic makeups could mount a strong immune response to the vaccine—something essential for global deployment.
Safety Verification Against Human Proteins
Using ImmunoPrecise's proprietary retrieve-and-relate technology at the core of HYFT™ (Van Hyfte et al., 2023, bioRxiv), the vaccine target was thoroughly compared against all known human and mouse proteins. This comprehensive safety check goes beyond standard comparison methods—HYFT systematically searches for not only genetic similarities but also structural and functional matches across species, ensuring the vaccine target is unique to the virus and not found in human biology. This is critical in vaccine development, where off-target effects can lead to dangerous autoimmune reactions. No problematic similarities were found, significantly reducing the risk that the vaccine would accidentally attack the body's own healthy cells.
Structural Stability Analysis
Advanced computer modeling and molecular simulation studies have confirmed that the vaccine target maintains its proper shape, remains accessible to immune cells, and remains prominently displayed on the surface of the dengue virus. Stability testing demonstrated that the target remains robust under normal physiological conditions.
Balanced Immune Response Profile
Importantly, the moderate predicted immune response strength (compared to typical vaccine 'hotspots') may explain why this target was overlooked in previous laboratory studies that focused on more obvious, highly immunogenic sites. This balanced profile suggests the vaccine could trigger a highly specific immune response while potentially reducing the risk of dangerous immune overreactions or antibody-dependent enhancement (ADE)—a serious complication that can worsen dengue infection.
Looking Ahead
This release is the second in a series of disclosures aimed at showcasing the power of ImmunoPrecise's end-to-end AI-native platform. The June 5th announcement introduced a promising target; today's release provides the crucial next step: a rigorous validation of that target's safety and immunological relevance. This validation significantly strengthens the translational potential of the candidate, which is currently being prepared for further preclinical evaluation.
These findings come at an important time, as global agencies continue to seek safer and more effective dengue vaccines. IPA is actively engaging with key stakeholders to explore the path forward, including potential collaboration, development, and funding partnerships.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, statements regarding the anticipated benefits, scalability, and broader application of the LENSai™ and HYFT® platforms to dengue vaccine development; the advancement, regulatory acceptance, and future clinical potential of AI-native approaches for dengue and other infectious diseases; and the Company's ability to achieve and maintain scientific, regulatory, and commercial progress in its dengue program.
Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, the pace of scientific and technological developments, changes in regulatory requirements or acceptance of AI designed vaccines, competition and market dynamics, intellectual property protection, risks related to preclinical or clinical validation of dengue vaccine candidates, integration and operational challenges, and changes in global economic or business conditions.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar). Should any of these risks materialize, actual results could vary significantly from those currently anticipated.
Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Capital Clean Energy Carriers Corp. Schedules Second Quarter 2025 Earnings Release, Conference Call and Webcast
Capital Clean Energy Carriers Corp. Schedules Second Quarter 2025 Earnings Release, Conference Call and Webcast

Yahoo

time21 minutes ago

  • Yahoo

Capital Clean Energy Carriers Corp. Schedules Second Quarter 2025 Earnings Release, Conference Call and Webcast

ATHENS, Greece, July 28, 2025 (GLOBE NEWSWIRE) -- Capital Clean Energy Carriers Corp. (NASDAQ: CCEC) today announced that before the NASDAQ market opens on July 31, 2025, CCEC will release financial results for the second quarter ended June 30, 2025. On the same day, Thursday, July 31, 2025, CCEC will host an interactive conference call at 8:00 a.m. Eastern Time to discuss the financial results. Conference Call Details: Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 877 405 1226 (US Toll-Free Dial In) or +1 201 689 7823 (US and Standard International Dial In). Please quote 'Capital Clean Energy' to the operator and/or conference ID 13754092. Click here for additional participant International Toll-Free access numbers. Alternatively, participants can register for the call using the call me option for a faster connection to join the conference call. You can enter your phone number and let the system call you right away. Click here for the call me option. Slides and Audio Webcast There will also be a live, and then archived, webcast of the conference call and accompanying slides, available through the Company's website. To listen to the archived audio file, visit our website and click on Webcasts & Presentations under our Investor Relations page. Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast. Add to CalendarTo easily add this event to your calendar, please use the following links: Outlook | Google Calendar About Capital Clean Energy Carriers Corp. Capital Clean Energy Carriers Corp. (NASDAQ: CCEC), an international shipping company, is one of the world's leading platforms of gas carriage solutions with a focus on energy transition. CCEC's in-the-water fleet includes 15 high specification vessels, including 12 latest generation LNG/Cs and three legacy Neo-Panamax container vessels. In addition, CCEC's under-construction fleet includes six additional latest generation LNG/Cs, six dual-fuel medium gas carriers and four handy LCO2/multi-gas carriers, to be delivered between the first quarter of 2026 and the third quarter of 2027. For more information about CCEC, please visit Contact Details: Investor Relations / MediaBrian GallagherEVP Investor RelationsTel. +44-(770) 368 4996E-mail: Nicolas Bornozis/ Markella Kara Capital Link, Inc. (New York) Tel. +1-212-661-7566E-mail: ccec@ in to access your portfolio

RGP Survey Shows CFOs Remain Cautiously Optimistic Amid Ongoing Uncertainty
RGP Survey Shows CFOs Remain Cautiously Optimistic Amid Ongoing Uncertainty

Yahoo

time21 minutes ago

  • Yahoo

RGP Survey Shows CFOs Remain Cautiously Optimistic Amid Ongoing Uncertainty

RGP's June 2025 CFO Survey illustrates how businesses are navigating market volatility DALLAS, July 28, 2025--(BUSINESS WIRE)--RGP® (Nasdaq: RGP), a professional services firm, today released new research that shows CFOs maintain cautious optimism about their organizations' current financial health and future outlook despite continued macroeconomic uncertainty. Nearly 70% of CFOs surveyed are positive about the current financial health of their organizations, and 60% are optimistic about their financial potential over the next 12 months. Yet, CFO optimism is tempered by growing concerns about tariff uncertainty and potential economic, supply chain, and geopolitical disruptions. The CFO findings are from a wider survey of 202 senior financial decision-makers — including 63 CFOs — from companies with more than $500 million in annual revenue. Respondents were asked how they are approaching strategic capital allocation in the next 12 months, which initiatives they are prioritizing, and the role they are playing in enterprise-wide decision-making. "Today's CFOs are shaping the way businesses are adapting, growing, and thriving amid rapid innovation, evolving risks, and unrelenting change," said Kate Duchene, Chief Executive Officer of RGP. "Not only are CFOs tasked with taking proactive steps to mitigate risks and maintain growth during this period of market volatility, but we are also seeing CFOs take more ownership of decisions related to workforce strategy, digital investment, and enterprise transformation. They are ideally positioned to provide a gauge of current business sentiment and outlook, and what we see is that CFOs remain focused on growth despite a lack of clarity around trade policy." Macroeconomic Outlook Most CFOs surveyed (94%) are concerned about tariff and trade policies, and most (63%) believe that supply chain disruptions are likely to occur in the next 12 months. The top actions CFOs are planning to take in response to tariff concerns include proactively cutting costs elsewhere (68%), supply chain diversification (44%), and engagement with policymakers and trade associations (41%). "In the last few years, businesses have had to navigate inflation, high interest rates, supply chain challenges, skills shortages, and ongoing market variability," said Jenn Ryu, Chief Financial Officer at RGP. "CFOs have led the charge in building agility and resilience into their business models to face these challenges, and we are now seeing them take proactive steps in response to tariff uncertainty. They are focused on advancing technological innovation, achieving operational excellence, and upskilling their workforce." Strategic Capital Allocation Most CFOs are directing the highest capital allocations to technology and digital transformation (57%), operational efficiency initiatives (57%), and product and service innovation (51%). Four in 10 CFOs plan to commit more than 10% of their capital budgets to AI initiatives in the next year. While many organizations remain in the early stages of AI adoption, RGP's findings show that both investment and optimism are growing as businesses begin to implement AI and see its benefits take shape. Eighty-four percent of CFOs are optimistic about the impact that AI will have on their business in the next 12 months and the same proportion is more optimistic in their outlook than they were 12 months ago. M&A Outlook CFOs are signaling strong interest in M&A, positioning 2025 as a potential banner year for strategic acquisitions. Half of CFOs anticipate engaging in M&A activity in the next six months with key focus areas including technology and capability acquisitions, horizontal acquisitions, and geographic expansions. But CFOs recognize that the difference between success and failure won't lie solely in financial modeling—it will hinge on integration excellence, cultural alignment, and the ability to bring people along on the journey. The CFO's role as both financial steward and change leader has never been more essential. "We entered this calendar year with expectations for increased M&A activity and many CFOs are gearing up for a more active second half," said Bhadresh Patel, Chief Operating Officer at RGP. "While regulatory scrutiny and lingering uncertainty add to the complexity of potential M&A activity, CFOs recognize that the success of any acquisition will hinge on integration excellence and cultural alignment." Conclusion The findings of RGP's research illuminate a compelling narrative: CFOs are at the forefront of shaping how their organizations adapt, grow, and thrive in an environment defined by rapid technological innovation, evolving risks, and unrelenting change. The message for 2025 is clear: lead boldly, collaborate cross-functionally, and build organizations that are as resilient as they are visionary. The RGP June 2025 CFO Survey polled senior financial decision-makers within the technology, financial services, healthcare and pharmaceutical industries and was conducted between May 27 and June 16, 2025. Read more about the findings here: ABOUT RGP RGP is a global professional services firm with nearly three decades of experience helping the world's top organizations—from Fortune 50 to fast-moving startups—solve today's complex business problems. A trusted partner to CFOs and finance leaders, we deliver the talent, consulting, and outsourced services solutions you need to grow faster, work smarter, and keep up with change—all through a flexible model and global network of experts. Based in Dallas, TX with offices worldwide, we annually engage with over 1,600 clients around the world from 41 physical practice offices and multiple virtual offices. RGP is proud to have served 88% of the Fortune 100 as of May 2025 and has been recognized by U.S. News & World Report (2024-2025 Best Companies to Work for) and Forbes (America's Best Management Consulting Firms 2025, America's Best Midsize Employers 2025, and World's Best Management Consulting Firms 2024). The Company is listed on the Nasdaq Global Select Market, the exchange's highest tier by listing standards. To learn more about RGP, visit: (RGP-F) View source version on Contacts Investor Contact:Jennifer Ryu, Chief Financial Officer(US+) Media Contact: Pat BurekFinancial Profiles(US+) 1-310-622-8244pburek@

MercadoLibre, Inc. to Report Second Quarter 2025 Financial Results
MercadoLibre, Inc. to Report Second Quarter 2025 Financial Results

Yahoo

time21 minutes ago

  • Yahoo

MercadoLibre, Inc. to Report Second Quarter 2025 Financial Results

Montevideo, July 28, 2025 (GLOBE NEWSWIRE) -- MercadoLibre, Inc. (Nasdaq: MELI) ( announces that it intends to release financial results for its second fiscal quarter ending June 30, 2025, on August 4, 2025. The Company will host its earnings results video conference, as well as a conference call and audio webcast, on August 4, at 5:00 p.m. Eastern Time. In order to access our video webcast and the live audio, investors, analysts and the market in general may access the following link at to attend the live event. To participate in our conference call Q&A, investors, analysts and the market in general may access the following link or dial in through the following numbers: TOLL FREE 1-833-821-3654 | INTERNATIONAL 1-412-652-1249 and ask to join MercadoLibre's conference call to be able to pose questions. Access to our video webcast and the live audio will be available in the investor relations section of the Company's website, at An archive of the webcast will be available for one week following the conclusion of the conference MercadoLibre MercadoLibre is the largest online commerce ecosystem in Latin America, based on unique visitors and processed orders, and is also one of the region's leading fintech platforms. Our efforts are centered on enabling e-commerce and digital financial services for our users by delivering a complete suite of technology solutions. The company is present in 18 countries including: Argentina, Brazil, Mexico, Colombia, Chile, Colombia and Peru. Through its e-commerce platform, MercadoLibre provides buyers and sellers with a robust and safe environment that fosters the development of a large e-commerce community in Latin America, a region with a population of over 650 million people and with one of the fastest-growing Internet penetration and e-commerce growth rates in the world. We believe that we offer world-class technological and commercial solutions that address the distinctive cultural and geographic challenges of operating a digital commerce platform in Latin America. Through its fintech platform, MercadoPago, the company offers a comprehensive set of financial technology services to users of its e-commerce platform, and to users outside of its e-commerce platform. For individuals, those services include a digital account that offers a debit card, online payments, insurance, savings, investments and credit lines. For merchants, MercadoPago offers online and physical point-of-sale payments processing services as well as the digital account. For more information about visit: Investor Relations Contact:investor@ Media Relations Contact: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store